Sign in
Taking people in United StatesPhase 3

Efgartigimod injections for adults with Graves' disease not controlled by thyroid medicines

Tests efgartigimod against placebo in adults with Graves' disease on antithyroid drugs.

Key facts

Who runs it
argenx
Where
Albany, Ann Arbor, Asheville, Carlsbad, Dallas, Dearborn, El Paso, Farmington Hills, Fleming Island, Fort Lauderdale, Houston, Irving, Jacksonville, Kansas City, Kissimmee, Lenexa, McAllen, McKinney, Mesquite, Miami, New York, Orange, Pasadena, Raleigh, San Jose, Shavano Park, and Wichita, United StatesSee the 29 sitesAlso in 2 other countries, 6 sites
Registry title
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease
Status
Recruiting
Phase
Phase 3
People taking part
230 people, planned
Started
10 Jun 2026
Expected to end
May 2030
Type of study
Interventional, 5 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Efgartigimod PH20 SC
  • Placebo PH20 SC
Record updated
3 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Graves' disease whose overactive thyroid is not well controlled by antithyroid drugs.

Age
18 years or older, and at least the local legal age of consent for clinical studies.
Sex
All sexes can join.
Disease stage
Active hyperthyroidism (overactive thyroid) caused by Graves' disease, with TSH (thyroid-stimulating hormone) <0.1 mIU/L at screening.
Earlier treatment
People must have taken MMI (methimazole) or CBZ (carbimazole) for at least 3 months before screening. People who had RAI (radioactive iodine) therapy or total removal of the thyroid cannot join.
Biomarker or test result
TRAb (anti-thyrotropin receptor antibody) levels at or above the upper limit of normal at screening.

Main reasons for not taking part

  • Overactive thyroid not caused by Graves' disease, such as toxic adenoma or toxic multinodular goiter.
  • Past RAI (radioactive iodine) therapy or total thyroid removal.
  • T3- or T4-containing medicine or supplement, such as levothyroxine, taken <6 weeks before screening.
  • Heart rhythm problems linked to Graves' disease, such as atrial fibrillation, not controlled enough with medicines.
  • Graves' eye disease that needs whole-body treatment, eye-socket injections, surgery or radiation, or such treatment planned during the study.

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Is at least 18 years of age and the local legal age of consent for clinical studies when signing the ICF
  • Has a documented diagnosis of GD with TRAb (anti-thyrotropin receptor antibody) levels >=ULN (upper limit of normal) at screening
  • Has active hyperthyroidism due to GD with TSH (thyroid-stimulating hormone) <0.1 mIU/L at screening
  • Has been treated with MMI (methimazole) or CBZ (carbimazole) for at least 3 months before screening

Who cannot take part

  • History of RAI (radioactive iodine) therapy or received a total thyroidectomy
  • T3- or T4-containing medication or supplement (eg, levothyroxine, liothyronine, desiccated thyroid preparations, or thyroid-support supplements) received <6 weeks before screening
  • History of hyperthyroidism not caused by GD (eg, toxic adenoma or toxic multinodular goiter)
  • Any complication of hyperthyroidism or underlying medical condition that would put the participant at undue risk. This includes arrhythmia or tachyarrhythmia related to GD, such as atrial fibrillation or atrial flutter not sufficiently controlled with medications
  • Graves' orbitopathy/Thyroid Eye Disease (GO/TED) requiring systemic therapy (eg, corticosteroids), orbital injections, orbital surgery, or orbital radiation, or expected immediate surgical intervention and/or planned corrective surgery/irradiation or medical therapy during the study

Where in United States

Also in 2 other countries, 6 sites

  • Albany Medical College Community EndocrinologyAlbany, United StatesContact: Robert BuschTaking people
  • University of MichiganAnn Arbor, United StatesContact: Tae-Hwa ChunTaking people
  • Asheville Clinical ResearchAsheville, United StatesContact: Lauren BernsteinTaking people
  • Profound Research LLC at Tri-City Primary CareCarlsbad, United StatesContact: Jamil Alkhaddo, MDTaking people
  • Research Institute Of DallasDallas, United StatesContact: Heidi Shea, MDTaking people
  • Metro Detroit Endocrinology CenterDearborn, United StatesContact: Ayman Elkadry, MDTaking people
  • Frontier Medical Center - Academy of Diabetes Thyroid and EndocrineEl Paso, United StatesContact: Sergio RovnerTaking people
  • Profound ResearchFarmington Hills, United StatesContact: Gary Edelson, MDTaking people
  • Northeast Florida Endocrine & Diabetes Associates (NEFEDA) - Orange Park LocationFleming Island, United StatesContact: Senan Sultan, MDTaking people
  • The Center for Diabetes and Endocrine CareFort Lauderdale, United StatesContact: Sam Lerman, MDTaking people
  • Clinic of EndocrinologyHouston, United StatesContact: Amir Hassan, MDTaking people
  • Juno ResearchHouston, United StatesContact: Damaris Vega, MDTaking people
  • Tekton Research IrvingIrving, United StatesContact: Pablo Mora, MDTaking people
  • University of Florida Jacksonville College of MedicineJacksonville, United StatesContact: Christian KochTaking people
  • Truman Medical CenterKansas City, United StatesContact: Rajib Bhattacharya, MDTaking people
  • Ilumina Medical Research LLCKissimmee, United StatesContact: Max Sosa-Pagan, MDTaking people
  • Johnson County Clin-Trials, Inc.Lenexa, United StatesContact: Thomas Kreamer, MDTaking people
  • Biopharma Informatic, LLCMcAllen, United StatesContact: Gloria Ortiz, MDTaking people
  • Tekton Research - McKinneyMcKinney, United StatesContact: Muhammad Siddiqui, MDTaking people
  • Southern Endocrinology Associates PAMesquite, United StatesContact: Sumana Gangi, MDTaking people
  • Oceane 7 Medical & Research Center, Inc.Miami, United StatesContact: Orlando FernandezTaking people
  • Endocrine Associates of West Village PCNew York, United StatesContact: Anastasios Manessis, MDTaking people
  • Diabetes Associates Medical GroupOrange, United StatesContact: Ivy-Joan Madu, MDTaking people
  • Havana Research Institute LLCPasadena, United StatesContact: John De Beixedon, MDTaking people
  • Pasadena Clinical TrialsPasadena, United StatesContact: Tzu-Jen TzaoTaking people
  • Wake Internal Medicine ConsultantsRaleigh, United StatesContact: Juman Takeddin, MDTaking people
  • San Jose Clinical TrialsSan Jose, United StatesContact: Richard CherlinTaking people
  • Consano Clinical ResearchShavano Park, United StatesContact: Daniel Katselnik, MDTaking people
  • Alliance for Multispecialty Research LLCWichita, United StatesContact: Terry KleinTaking people

About the trial

What the trial wants to find out

The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody levels, and how the immune system responds to it.

Read full original descriptionShow less

The study consists of a part A double-blinded treatment period, a part B treatment/observation period and a part C open-label treatment/observation period. During the part A and part B treatment periods, participants will receive efgartigimod PH20 SC via Prefilled Syringe (PFS) or placebo. During the part C open-label treatment period, participants will receive efgartigimod PH20 SC PFS. Participation in the different parts of the study will depend on the participant's response to treatment.

The total study duration for participants ranges from 63 to 135 weeks, depending on the response to treatment.

More information can be found here: https://clinicaltrials.argenx.com/vitalithy

The 5 groups in the trial

  • Part A - efgartigimod PH20 SC PFSTreatment being tested

    Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period.

    Treatment: Efgartigimod PH20 SC

  • Part A - placebo PH20 SC PFSPlacebo, for comparison

    Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period.

    Treatment: Placebo PH20 SC

  • Part B - efgartigimod PH20 SC PFSTreatment being tested

    Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period.

    Treatment: Efgartigimod PH20 SC

  • Part B - placebo PH20 SC PFSTreatment being tested

    Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period.

    Treatment: Placebo PH20 SC

  • Part C - efgartigimod PH20 SC PFSTreatment being tested

    Participants will receive efgartigimod PH20 SC PFS in the part C open-label treatment period

    Treatment: Efgartigimod PH20 SC

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid Drugs
Plain-language title
Efgartigimod injections for adults with Graves' disease not controlled by thyroid medicinesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
3 November 2026